Schering-Plough's Temodar Gets Priority Review For First-Line Glioma
This article was originally published in The Pink Sheet Daily
Executive Summary
The supplemental application has a user fee goal date of March 2005. Phase II/III trials of the oral cytotoxic alkylating agent are ongoing for treatment of brain metastases from various cancers.